Advanced

Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS

Woodmansee, Whitney W.; Zimmermann, Alan G.; Child, Christopher J.; Rong, Qi; Erfurth, Eva Marie LU ; Beck-Peccoz, Paolo; Blum, Werner F. and Robison, Leslie L. (2013) In European Journal of Endocrinology1994-01-01+01:00 168(4). p.565-573
Abstract
Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors. We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and... (More)
Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors. We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (< 3 years), longer observation is recommended. Nevertheless, clinicians should be alerted to the possibility of increased risk of SN in childhood cancer survivors treated with GH and continue chronic surveillance. European Journal of Endocrinology 168 565-573 (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Endocrinology1994-01-01+01:00
volume
168
issue
4
pages
565 - 573
publisher
Society of the European Journal of Endocrinology
external identifiers
  • wos:000317478700015
  • scopus:84875127775
ISSN
1479-683X
DOI
10.1530/EJE-12-0967
language
English
LU publication?
yes
id
05d31ceb-9edd-4444-b17b-e5b14e2c9569 (old id 3739161)
date added to LUP
2013-06-03 08:32:44
date last changed
2019-04-10 01:29:44
@article{05d31ceb-9edd-4444-b17b-e5b14e2c9569,
  abstract     = {Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors. We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (&lt; 3 years), longer observation is recommended. Nevertheless, clinicians should be alerted to the possibility of increased risk of SN in childhood cancer survivors treated with GH and continue chronic surveillance. European Journal of Endocrinology 168 565-573},
  author       = {Woodmansee, Whitney W. and Zimmermann, Alan G. and Child, Christopher J. and Rong, Qi and Erfurth, Eva Marie and Beck-Peccoz, Paolo and Blum, Werner F. and Robison, Leslie L.},
  issn         = {1479-683X},
  language     = {eng},
  number       = {4},
  pages        = {565--573},
  publisher    = {Society of the European Journal of Endocrinology},
  series       = {European Journal of Endocrinology1994-01-01+01:00},
  title        = {Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS},
  url          = {http://dx.doi.org/10.1530/EJE-12-0967},
  volume       = {168},
  year         = {2013},
}